Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium

医学 临床试验 微生物群 生物技术 业务 重症监护医学 生物信息学 病理 生物
作者
Ching‐Hung Tseng,Sunny H. Wong,Jun Yu,Yeong Yeh Lee,Jun Terauchi,Hsin‐Chih Lai,Jiing‐Chyuan Luo,Cheng‐Yen Kao,Sung‐Liang Yu,Jyh‐Ming Liou,Deng‐Chyang Wu,Ming‐Chih Hou,Ming-Shiang Wu,Jiunn‐Jong Wu,Joseph J.�Y. Sung,Emad El‐Omar,Chun‐Ying Wu
出处
期刊:Gut [BMJ]
卷期号:: gutjnl-334501
标识
DOI:10.1136/gutjnl-2024-334501
摘要

Objective Live biotherapeutic products (LBPs) are biological products composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains of Akkermansia muciniphila and Christensenella minuta , as well as treatments using purified Firmicutes spores for recurrent Clostridioides difficile infections. There is a need for guidelines over the increasing interest in developing LBPs. A panel of microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations for LBP development. Design Experts in microbiome research, microbiology, gastroenterology, internal medicine and biotherapeutics industry were invited to form a panel. During the 2023 Inauguration Conference of the Asia-Pacific Microbiota Consortium, an organised, iterative roundtable discussion was conducted to build expert consensus on critical issues surrounding the development of LBP. Results The consensus statements were organised into three main aspects: (a) rationales of LBP development, (b) preclinical studies and (c) preparation for clinical studies. The panel strongly recommended to prioritise human-derived and food-sourced strains for development, with indications based on clinical need and efficacy shown in studies. Preclinical evaluation should involve thorough screening, genotyping and phenotyping, as well as comprehensive in vitro and animal studies to assess functional mechanisms and microbiological safety. Rigorous cell banking practices and genetic monitoring are essential to ensure product consistency and safety throughout the manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed and closely monitored, with robust safety and risk management protocols in place. Conclusions The development of LBP should be approached with a strong emphasis on microbiological evaluation, clinical relevance, scientific mechanisms and safety at every stage. These measures are essential to ensure the safety, effectiveness and long-term success of the product.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘师兄吧完成签到,获得积分10
刚刚
橘猫不长橘毛完成签到,获得积分10
刚刚
Trista完成签到,获得积分10
1秒前
东方立轩发布了新的文献求助10
1秒前
白衣修身完成签到,获得积分10
1秒前
ning完成签到,获得积分10
1秒前
hi_zhanghao完成签到,获得积分0
2秒前
2秒前
小蘑菇应助CPELQY采纳,获得10
4秒前
Valorwolf完成签到,获得积分10
4秒前
4秒前
大分子完成签到,获得积分10
5秒前
wdd完成签到 ,获得积分10
6秒前
独摇之完成签到,获得积分10
6秒前
东方立轩完成签到,获得积分10
6秒前
如意完成签到,获得积分10
7秒前
HEROTREE完成签到 ,获得积分10
8秒前
王大锤完成签到,获得积分10
8秒前
YANG完成签到 ,获得积分10
8秒前
乐乐应助壮观的雅山采纳,获得30
8秒前
王小凡完成签到 ,获得积分10
8秒前
研友_85YNe8完成签到,获得积分10
9秒前
斯文败类应助lh采纳,获得10
9秒前
吴鹏发布了新的文献求助10
9秒前
badada发布了新的文献求助10
10秒前
七月完成签到 ,获得积分10
10秒前
锅锅完成签到,获得积分10
10秒前
徐慕源完成签到,获得积分10
10秒前
ly完成签到,获得积分20
11秒前
那种完成签到,获得积分10
11秒前
阿尔治完成签到,获得积分10
11秒前
wenhao完成签到 ,获得积分10
11秒前
763完成签到 ,获得积分10
12秒前
shuogesama完成签到,获得积分10
12秒前
啦啦咔嘞完成签到,获得积分10
12秒前
袁硕完成签到 ,获得积分10
13秒前
LGH完成签到 ,获得积分10
14秒前
七七完成签到,获得积分10
14秒前
田様应助哈哈采纳,获得10
14秒前
关我屁事完成签到 ,获得积分10
14秒前
高分求助中
Continuum Thermodynamics and Material Modelling 4000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
El viaje de una vida: Memorias de María Lecea 800
Theory of Block Polymer Self-Assembly 750
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3510987
求助须知:如何正确求助?哪些是违规求助? 3093692
关于积分的说明 9218660
捐赠科研通 2788179
什么是DOI,文献DOI怎么找? 1530009
邀请新用户注册赠送积分活动 710726
科研通“疑难数据库(出版商)”最低求助积分说明 706329